The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate

Experimental Hematology

Volumn 31, Issue 8, 2003, Pages 702-707

  Feldman, Eric ^a   Najfeld, Vesna ^b   Schuster, Michael ^a   Roboz, Gail ^a   Chadburn, Amy ^a   Silver, Richard T ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOGENETICS; DISEASE COURSE; DOSE RESPONSE; DRUG WITHDRAWAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HEMATOLOGY; HUMAN; HUMAN TISSUE; INTERPHASE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; METAPHASE; MOLECULAR CLONING; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0042167270     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(03)00176-0     Document Type: Article

References (22)

1. Faderl S., Talpaz M., Estrov Z., Kantarjian H.M. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med. 131:(3):1999;207-219.
2. Nowell P.C., Finan J.B., Weiss A. Karyotypic and clinical progression in chronic myelogenous leukemia after 30 years. Cancer Genet Cytogenet. 60:(1):1992;96-98.
3. Rowley J.D. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and giemsa staining. Nature. 243:1973;290-293.
4. Lugo T.G., Pendergast A.M., Muller A.J., Witte O.N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 247:1990;1079-1082.
5. Deininger M., Goldman J., Melo J. The molecular biology of chronic myeloid leukemia. Blood. 96:2000;3343-3356.
6. Griesshammer M., Heinze B., Bangerter M., Heimpel H., Fliedner T.M. Karyotype abnormalities and their clinical significance in blast crisis of chronic myeloid leukemia. J Mol Med. 75:1997;836-838.
7. Daley G.Q., Van Etten R.A., Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210 bcr/abl gene of the Philadelphia chromosome. Science. 247:1990;824-830.
8. Druker B.J., Tamura S., Buchdunger E., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 2:1996;561-566.
9. Mauro M.J., O'Dwyer M.E., Druker B.J. ST1571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy. Cancer Chemother Pharmacol. 48:(suppl):2001.
10. Capdeville R., Buchdunger E., Zimmermann J., Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov. 1:2002;493-502.
11. Kantarjian H., Sawyers C., Hochhaus A., et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 346:2002;645-652.
12. + chronic myeloid leukemia (CML): Results of a randomized phase III study vs interferon-alfa and cytarabine (IFN+ara-C). Proceedings of the American Society of Hematology. 2002;. Abstract 2.
13. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 347:2002;472-480.
14. Andersen M.K., Pedersen-Bjergaard J., Kjeldsen L., et al. Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8. Leukemia. 7:2002;1390-1393.
15. - cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood. 101:2003;1941-1949.
16. Medina J., Kantarjian H., Talpaz M., et al. Chromosomal abnormalities in Philadelphia chromosome (Ph) negative metaphases appearing during treatment with imatinib mesylate in patients with Ph positive chronic myeloid leukemia in chronic phase. Blood. 100:2002;368a. Abstract 1423.
17. O'Dwyer M.E., Gatter K.M., Loriaux M., et al. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia. 17:(3):2003 Mar;481-487.
18. Paulsson K., Sall T., Fioretos T., et al. The incidence of trisomy 8 as a sole chromosomal aberration in myeloid malignancies varies in relation to gender, age, prior iatrogenic genotoxic exposure, and morphology. Cancer Genet Cytogenet. 2:2001;160-165.
19. Byrd J.C., Lawrence D., Arthur D.C., et al. Patients with isolated trisomy 8 in acute myeloid leukemia are not cured with cytarabine-based chemotherapy: results from Cancer and Leukemia Group B 8461. Clin Cancer Res. 4:1998;1235-1241.
20. Fayad L., Kantarjian H., O'Brien S., et al. Emergence of new clonal abnormalities following interferon-α induced complete cytogenetic response in patients with chronic myeloid leukemia: report of three cases. Leukemia. 11:1997;767-771.
21. Fialkow P.J., Martin P.J., Najfeld V., et al. Evidence for a multistep pathogenesis of chronic myelogenous leukemia. Blood. 58:1981;158-163.
22. Martin P.J., Najfeld V., Fialkow P.J. B-lymphoid cell involvement in chronic myelogenous leukemia: implications for the pathogenesis of the disease. Cancer Genet Cytogenet. 6:1982;359-368.